Professor Michael S. Hofman
Professor Michael S. Hofman
Consultant Physician, Peter MacCallum Cancer Centre & University of Melbourne
Verified email at
TitleCited byYear
Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and …
M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ...
European urology 70 (6), 926-937, 2016
International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ...
Journal of Nuclear Medicine 54 (5), 683-690, 2013
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ...
Haematologica 99 (6), 1107-1113, 2014
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
MS Hofman, G Kong, OC Neels, P Eu, E Hong, RJ Hicks
Journal of medical imaging and radiation oncology 56 (1), 40-47, 2012
Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation
MS Hofman, WFE Lau, RJ Hicks
Radiographics 35 (2), 500-516, 2015
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ...
The Lancet Oncology 19 (6), 825-833, 2018
Is there still a role for SPECT–CT in oncology in the PET–CT era?
RJ Hicks, MS Hofman
Nature reviews Clinical oncology 9 (12), 712, 2012
Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
JM Beauregard, MS Hofman, JM Pereira, P Eu, RJ Hicks
Cancer Imaging 11 (1), 56, 2011
Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT
RJ Clifton-Bligh, MS Hofman, E Duncan, IW Sim, D Darnell, A Clarkson, ...
The Journal of Clinical Endocrinology & Metabolism 98 (2), 687-694, 2013
68Ga PET/CT ventilation–perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy
MS Hofman, JM Beauregard, TW Barber, OC Neels, P Eu, RJ Hicks
Journal of Nuclear Medicine 52 (10), 1513-1519, 2011
Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, ...
British journal of cancer 109 (2), 312, 2013
Validating and improving CT ventilation imaging by correlating with ventilation 4D‐PET/CT using 68Ga‐labeled nanoparticles
J Kipritidis, S Siva, MS Hofman, J Callahan, RJ Hicks, PJ Keall
Medical physics 41 (1), 2014
Prostate-specific membrane antigen ligands for imaging and therapy
M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ...
J Nucl Med 58 (Suppl 2), 67S-76S, 2017
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
JM Beauregard, MS Hofman, G Kong, RJ Hicks
European journal of nuclear medicine and molecular imaging 39 (1), 50-56, 2012
Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients
E Quak, PY Le Roux, MS Hofman, P Robin, D Bourhis, J Callahan, ...
European journal of nuclear medicine and molecular imaging 42 (13), 2072-2082, 2015
Changing paradigms with molecular imaging of neuroendocrine tumors
MS Hofman, RJ Hicks
Discovery medicine 14 (74), 71-81, 2012
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
G Kong, M Thompson, M Collins, A Herschtal, MS Hofman, V Johnston, ...
European journal of nuclear medicine and molecular imaging 41 (10), 1831-1844, 2014
Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
R Kashyap, MS Hofman, M Michael, G Kong, T Akhurst, P Eu, D Zannino, ...
European journal of nuclear medicine and molecular imaging 42 (2), 176-185, 2015
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable
TW Barber, MS Hofman, BNJ Thomson, RJ Hicks
European Journal of Surgical Oncology (EJSO) 38 (1), 64-71, 2012
68 Ga-DOTATATE and 18 F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
CA Chang, DA Pattison, RW Tothill, G Kong, TJ Akhurst, RJ Hicks, ...
Cancer Imaging 16 (1), 22, 2016
The system can't perform the operation now. Try again later.
Articles 1–20